Mukka Proteins Q3 FY26 Revenue Surges 115.57% YoY to ₹653.50 Cr; Secures ₹474.89 Cr Order
Mukka Proteins reported a strong Q3 FY26 with revenue soaring 115.57% YoY to ₹653.50 crore. The company secured a ₹474.89 crore order for leachate treatment and is expanding its carbon credit portfolio. EBITDA for Q3 FY26 was ₹53.21 crore and PAT was ₹27.25 crore.
The substantial revenue growth, diversification into a large-value waste management project, and expansion in ESG initiatives are material events for the company.
The company reported significant year-on-year growth in revenue and secured a large order for a new business segment, along with progress in ESG initiatives.
Mukka Proteins Limited announced its unaudited Financial Results for the Quarter and Nine months ended December 31, 2025 (Q3 and 9M FY26).
For Q3 FY26, the company reported a consolidated revenue from operations of ₹653.50 crore, marking a significant year-on-year increase of 115.57% and a quarter-on-quarter increase of 167.19%. EBITDA stood at ₹53.21 crore with margins at 8.14%, and Profit After Tax (PAT) was ₹27.25 crore with margins at 4.17%.
For the nine months ended December 31, 2025 (9MFY26), consolidated revenue from operations reached ₹1,068.85 crore, a 71.06% increase YoY. EBITDA for 9MFY26 was ₹96.15 crore, and PAT was ₹35.73 crore.
In a strategic diversification, the company secured a first-of-its-kind order worth ₹474.89 crore for the scientific treatment and disposal of legacy leachate from Bengaluru Solid Waste Management Limited (BSWML).
The company also highlighted its ESG initiatives, strengthening its carbon credit portfolio with a Verra-listed BSF project. Its 300 TPD wet waste processing operations are advancing toward carbon credit issuance, and an incremental approval for 1,000 TPD operations has been received.
Mr. Kalandan Mohammed Haris, CEO & MD, stated that the strong performance is driven by benefiting from global fishmeal supply tightness and cost-optimization initiatives. He also mentioned strategic investments in subsidiaries like Haris Marine Products Pvt. Ltd. and Ento Proteins Pvt. Ltd.
Mukka Proteins Limited is a prominent manufacturer and exporter of fishmeal, fish oil, and fish-soluble paste, with a significant market share in India and a presence in over 25 countries.
What to do with a filing like this
Mukka Proteins Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mukka Proteins Limited. Read the original for the full detail.